Genscript Biotech Corporation (GNNSF)
USD 1.5
(-21.0%)
USD 1.5
(-21.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.06 Billion USD | -57.42% |
| 2022 | -674.2 Million USD | 34.19% |
| 2021 | -1.02 Billion USD | -78.47% |
| 2020 | -574.05 Million USD | -151.49% |
| 2019 | -228.26 Million USD | 52.84% |
| 2018 | -484.05 Million USD | -294.34% |
| 2017 | -122.75 Million USD | 10.02% |
| 2016 | -136.41 Million USD | -31.52% |
| 2015 | -103.72 Million USD | -493.87% |
| 2014 | -17.46 Million USD | -15.92% |
| 2013 | -15.06 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 477.87 Million USD | 145.03% |
| 2024 Q2 | 477.87 Million USD | 23.45% |
| 2023 Q1 | -525.3 Million USD | 22.08% |
| 2023 Q3 | -612.76 Million USD | 39.71% |
| 2023 Q2 | -1.01 Billion USD | -93.5% |
| 2023 FY | -1.06 Billion USD | -57.42% |
| 2023 Q4 | -1.06 Billion USD | -73.2% |
| 2022 Q4 | -674.2 Million USD | -77.85% |
| 2022 Q3 | -379.08 Million USD | 31.45% |
| 2022 Q2 | -553.01 Million USD | -91.7% |
| 2022 Q1 | -288.48 Million USD | 71.84% |
| 2022 FY | -674.2 Million USD | 34.19% |
| 2021 Q3 | -771.24 Million USD | 14.48% |
| 2021 Q4 | -1.02 Billion USD | -32.84% |
| 2021 Q2 | -901.81 Million USD | 0.52% |
| 2021 Q1 | -906.56 Million USD | -57.92% |
| 2021 FY | -1.02 Billion USD | -78.47% |
| 2020 Q3 | -576.64 Million USD | 11.04% |
| 2020 FY | -574.05 Million USD | -151.49% |
| 2020 Q1 | -650.53 Million USD | -184.99% |
| 2020 Q2 | -648.18 Million USD | 0.36% |
| 2020 Q4 | -574.05 Million USD | 0.45% |
| 2019 Q4 | -228.26 Million USD | 0.77% |
| 2019 Q3 | -230.03 Million USD | 11.15% |
| 2019 Q2 | -258.89 Million USD | 0.53% |
| 2019 Q1 | -260.27 Million USD | 46.23% |
| 2019 FY | -228.26 Million USD | 52.84% |
| 2018 Q3 | -484.05 Million USD | -7.09% |
| 2018 Q1 | -452 Million USD | -264.94% |
| 2018 Q2 | -452 Million USD | 0.0% |
| 2018 Q4 | -484.05 Million USD | 0.0% |
| 2018 FY | -484.05 Million USD | -294.34% |
| 2017 Q3 | -123.85 Million USD | 5.27% |
| 2017 FY | -122.75 Million USD | 10.02% |
| 2017 Q4 | -123.85 Million USD | 0.0% |
| 2017 Q2 | -130.74 Million USD | 0.0% |
| 2017 Q1 | -130.74 Million USD | 4.19% |
| 2016 Q3 | -136.46 Million USD | -12.94% |
| 2016 Q4 | -136.46 Million USD | 0.0% |
| 2016 FY | -136.41 Million USD | -31.52% |
| 2016 Q2 | -120.83 Million USD | 0.0% |
| 2016 Q1 | -120.83 Million USD | -16.5% |
| 2015 Q3 | -103.72 Million USD | -303.83% |
| 2015 Q1 | -25.68 Million USD | -47.06% |
| 2015 Q4 | -103.72 Million USD | 0.0% |
| 2015 FY | -103.72 Million USD | -493.87% |
| 2015 Q2 | -25.68 Million USD | 0.0% |
| 2014 Q1 | 26.56 Million USD | 0.0% |
| 2014 FY | -17.46 Million USD | -15.92% |
| 2014 Q4 | -17.46 Million USD | 0.0% |
| 2014 Q3 | -17.46 Million USD | 0.0% |
| 2013 FY | -15.06 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -81017834.046% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 18890.11% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 2580.16% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -425080.248% |
| Rebus Holdings, Inc. | 305 Thousand USD | 348078.668% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -16734.498% |
| Qrons Inc. | 351.42 Thousand USD | 302107.227% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 170632.829% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 2543.558% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -5200482.791% |
| Skye Bioscience, Inc. | -5.72 Million USD | -18450.302% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 6833.077% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 25872.918% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 264212.872% |
| SQZ Biotechnologies Company | -36.23 Million USD | -2828.79% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 47433.838% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 114568.395% |
| Mesoblast Limited | 55.85 Million USD | 2000.05% |
| Marizyme, Inc. | 18.56 Million USD | 5815.619% |
| Genus plc | 190.6 Million USD | 656.839% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 47569.351% |
| Pharming Group N.V. | 109.8 Million USD | 1066.572% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 123476.465% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 87532.69% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 156178.667% |
| ContraFect Corporation | -6.02 Million USD | -17512.594% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 788381.951% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 91956.353% |
| IMV Inc. | 7.67 Million USD | 13936.543% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 19390.349% |
| MultiCell Technologies, Inc. | 90.04 USD | 1178737256.819% |
| ONE Bio Corp. | 9.04 Million USD | 11840.385% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -144500.374% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 8298.169% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 77684.608% |
| Q BioMed Inc. | 4.06 Million USD | 26241.203% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 3573.637% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 105420.838% |
| Biomind Labs Inc. | 711.4 Thousand USD | 149289.198% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 1852.947% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 53182.884% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 8387.412% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 295152.942% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 759259.206% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 5342300.312% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 48299.096% |
| GB Sciences, Inc. | 1.74 Million USD | 60840.87% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -577377.82% |
| HST Global, Inc. | 96.79 Thousand USD | 1096599.681% |
| CSL Limited | 10.52 Billion USD | 110.083% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 514768.983% |
| Halberd Corporation | 144.72 Thousand USD | 733466.226% |
| Enzolytics Inc. | 981.65 Thousand USD | 108216.788% |
| Agentix Corp. | 37.63 Thousand USD | 2820473.99% |
| Resverlogix Corp. | 6.45 Million USD | 16552.254% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -157581.218% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 47.688% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -2157.583% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 15109.746% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 39283.676% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -11906.171% |
| AVAX Technologies, Inc. | -5.9 Million USD | -17878.955% |
| Zenith Capital Corp. | 10.06 Thousand USD | 10545955.882% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 529623.697% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 44581.132% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 645253.114% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -5793845.496% |
| Kadimastem Ltd | -253.1 Thousand USD | -419230.916% |
| Helix BioMedix, Inc. | -2.57 Million USD | -41196.565% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 5334.439% |
| BioStem Technologies, Inc. | 4.47 Million USD | 23832.834% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 527460.915% |
| LadRx Corporation | -2.03 Million USD | -52016.43% |
| Cell Source, Inc. | 9.23 Million USD | 11596.298% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 167195.415% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 167195.415% |
| NovAccess Global Inc. | 2.17 Million USD | 48819.394% |
| Affymax, Inc. | -5.59 Million USD | -18862.568% |
| Itoco Inc. | 228.3 Thousand USD | 464975.905% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 780556.46% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 21510.832% |
| Mobile Lads Corp. | 484.23 Thousand USD | 219279.017% |
| CytoDyn Inc. | 20.26 Million USD | 5338.056% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -164039302.782% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -11451086.901% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 13872.835% |
| SYBLEU INC | 473.71 Thousand USD | 224145.508% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 23912.647% |
| International Stem Cell Corporation | 2.59 Million USD | 41078.183% |
| Bioxytran, Inc. | 1.89 Million USD | 55991.68% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 1700602.998% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 48764.998% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 31006.667% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 12508.92% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 137470.608% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -84806.795% |
| Neutra Corp. | 52.18 Thousand USD | 2033815.17% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -42541.018% |
| PureTech Health plc | -167.19 Million USD | -534.781% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -433260.664% |
| IXICO plc | -4.44 Million USD | -23779.27% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 8128.859% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 2034.942% |
| CSL Limited | 10.52 Billion USD | 110.083% |
| Cellectis S.A. | -43.81 Million USD | -2322.095% |